Nautilus Biotechnology Inc
NAUT
Company Profile
Business description
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Contact
2701 Eastlake Avenue East
SeattleWA98102
USAT: +1 206 333-2001
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
130
Stocks News & Analysis
stocks
CBA earnings: Business lending powers on, but costs and credit bear watching
Our view after the bank reports first quarter earnings.
stocks
Apple earnings review: Revenue beats estimates as memory crunch threatens margins
Apple shares are trading at record highs after posting solid results.
stocks
Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil
We’re reducing our long-term revenue estimates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.50 | 69.70 | -0.75% |
| CAC 40 | 8,368.91 | 7.55 | 0.09% |
| DAX 40 | 26,749.95 | 21.93 | -0.08% |
| Dow JONES (US) | 52,347.55 | 50.46 | 0.10% |
| FTSE 100 | 10,902.56 | 39.47 | 0.36% |
| HKSE | 23,637.60 | 370.95 | -1.55% |
| NASDAQ | 25,136.27 | 229.82 | -0.91% |
| Nikkei 225 | 61,142.35 | 322.99 | 0.53% |
| NZX 50 Index | 14,173.68 | 85.55 | -0.60% |
| S&P 500 | 7,561.67 | 30.73 | -0.40% |
| S&P/ASX 200 | 9,082.20 | 64.60 | -0.71% |
| SSE Composite Index | 3,634.35 | 21.48 | -0.59% |